#HEP_highlights Before the biopsy: Accuracy of NITs in NAFLD patients with T2DM Pennisi G et al. LSM and AGILE 3+ individually or in sequential combination after FIB-4 or NFS have a similar good diagnostic accuracy for advanced fibrosis #LiverTwitter shorturl.at/xyzU6

Newly published HRS Harmony study: Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US - Journal of Hepatology journal-of-hepatology.eu/article/S0168-…

Congratulations to our 2023 AASLD Foundation Award Recipients! 🎉Award recipients were selected from a highly competitive applicant pool, demonstrate an exceptional aptitude, and have a deep interest in #liver disease research and treatment. Read more at bit.ly/43QuhoR.

A global action agenda for turning the tide on fatty liver disease in HEPATOLOGY Journal 🚨To implement this agenda, concerted efforts will be needed at the global, regional, and national levels. #LiverTwitter shorturl.at/duwHY

#HEP_highlight Saving Livers, One Blocker at a Time: A Bayesian Twist on CLD Management ✅Beta-blocker treatment is associated with a high probability of clinical benefit #LiverTwitter tinyurl.com/yr4dc8mh

REVIEW‼️ Friedman S & Sanyal A. The future of hepatology: ✅Basic and translational science ✅Data management ✅Artificial intelligence ✅Precision medicine shorturl.at/eh145

1/15 🤔Why does portal hypertension lead to splenomegaly. I also assumed the spleen became "congested" from backflow of blood. Turns out, it isn't that simple. And there are interesting therapeutic implications. Let's have a look.

Hi! We were fortunate to spend time with Amit G Singal to talk about the latest @AASLD HCC guidelines. In a new segment, we have HEPATOLOGY Journal editorial fellow Rob Wilechansky on to discuss outcomes from NASH clinical trial. Liver Fellow Network @UTSWNews 🍏: podcasts.apple.com/gh/podcast/div…

🚨 AASLD Practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis 🚨 JUST RELEASED shorturl.at/agEI1 #LiverTwitter #LiverX

🆕REVIEW: Digital pathology and artificial intelligence in non-alcoholic steatohepatitis ➡️Current status and future directions. Read it here👉 bit.ly/3Qlsnbh via Journal of Hepatology #LiverTwitter

New episode! New host! We're ecstatic to welcome our new fellow lead #PatrickLee from USC Division of GI & Liver. Discussion is centered around finding a job, negotiation etc. We welcome back Rob Wilechansky to discuss what's new in HEPATOLOGY Journal. Liver Fellow Network AASLD

Great to see the Liver Transplantation Journal (LTxJournal) & HEPATOLOGY Journal editorial fellows together at #TLM23 - Alan L. Hutchison, MD, PhD (he/him) & Rob Wilechansky! 🔥 #livertwitter

While waiting for prohibitively expensive meds to be FDA approved for MASLD/MASH… this high-quality *RCT* demonstrated that 6 months of ASPIRIN reduced - Liver Fat❗️ - liver stiffness, liver enzymes, cT1❗️❗️ By: Tracey Simon Khalili Rob Wilechansky @KathleenCoreyMD Ray Chung

Our DECEMBER ISSUE is live! Alcohol-related liver disease and MASLD, HCC surveillance, intestinal hormones, IBD, and much more! nature.com/nrgastro/volum…

Did you know about our new Fellows' Corner? Keeping up with an ever-evolving literature during GI and hepatology training is not an easy task. Here Rob Wilechansky discuss 3 papers with meaningful developments for diagnostics and therapeutics in hepatology! tinyurl.com/3uyc8628

Big month for #MASLD trials - as we discuss costs of medications, nice to see the potential of low-cost alternatives. Congratulations to my favorite Tracey Simon Khalili (proud of you friend) and Rob Wilechansky @KathleenCoreyMD Rohit Loomba Ray Chung Andy Chan MGH Division of Gastroenterology #livertwitter #mash

Targeting MAP is crucial to hasten AKI recovery. See➡️ journals.lww.com/hep/fulltext/9… by the mad genius Giuseppe Cullaro Need more evidence? ➡️ pubmed.ncbi.nlm.nih.gov/32618694/ ➡️ pubmed.ncbi.nlm.nih.gov/38535488/ AASLD Global Aki HRS Harmony

Hot off the press: Survodutide efficacy in#MASH including both MASH resolution & fibrosis improvement presented ⁦EASL Education⁩ and published ⁦NEJM⁩ today! ⁦Arun J. Sanyal⁩ ⁦Naim Alkhouri⁩ ⁦Ramy Younes, MD, PhD⁩ #livertwitter

Big news in the world of liver disease! The FDA has approved Elafibranor for patients with PBC. This is a huge step forward in the treatment of this chronic condition and offers new hope to those affected. #PBC #Elafibranor #FDAapproval

📑 A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of #cirrhosis❕ #NLP #LiverTwitter #LiverX